Physician profile
Simona Meca
NPI 1649415035
$4,215.33
in general payments reported to CMS, 2019-2025
32 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $323 · 2021: $1,009 · 2022: $824 · 2023: $528 · 2024: $287 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,114.79 | 2019-2025 | Xifaxan, Plenvu |
| Abbvie INC. | $1,105.86 | 2019-2025 | |
| Braintree Laboratories, INC. | $229.86 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.15 | 2019-2023 | Entyvio |
| Pfizer INC. | $206.25 | 2019-2025 | |
| Celgene Corporation | $167.45 | 2022-2024 | Zeposia |
| Boston Scientific Corporation | $134.56 | 2022 | |
| Janssen Biotech, INC. | $103.72 | 2019-2024 | Stelara |
| Ferring Pharmaceuticals INC. | $82.25 | 2019-2024 | Rebyota |
| Gilead Sciences, INC. | $79.54 | 2019-2025 | |
| Ucb, INC. | $74.80 | 2019 | |
| Currax Pharmaceuticals LLC | $73.13 | 2021 | |
| Endo Pharmaceuticals INC. | $66.39 | 2019-2020 | |
| Baxter Healthcare | $57.62 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Lilly USA, LLC | $55.21 | 2023-2024 | Zepbound, Jardiance, Mounjaro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $54.48 | 2021-2023 | Linzess |
| Novo Nordisk INC | $53.74 | 2021-2025 | Wegovy |
| Alfasigma USA, INC. | $35.73 | 2020 | |
| Madrigal Pharmaceuticals | $33.75 | 2024 | Resmetirom |
| Qol Medical, LLC | $32.41 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $25.36 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $24.51 | 2019-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $24.27 | 2021 | |
| Concordia Pharmaceuticals INC. | $24.18 | 2019 | |
| Genzyme Corporation | $21.95 | 2023 | |
| Daiichi Sankyo INC. | $19.26 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.70 | 2019 | |
| Ardelyx, INC. | $15.91 | 2024 | Ibsrela |
| Astrazeneca Pharmaceuticals Lp | $15.71 | 2020 | |
| Fresenius Kabi USA, LLC | $12.97 | 2023 | |
| Curium US LLC | $12.92 | 2022 | |
| Amgen INC. | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simona Meca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.